Literature DB >> 7978676

Nephrogenic diabetes insipidus secondary to lithium therapy in the postoperative patient: a case report.

M A Johnson1, J Ogorman, G H Golembiewski, M W Paluzzi.   

Abstract

Nephrogenic diabetes insipidus (NDI) presents a rarely encountered but challenging fluid management problem in the perioperative period. This case is that of a patient with a perforated duodenal ulcer and previously undiagnosed NDI who received standard preoperative and postoperative hydration with normal saline, causing hypernatremia and an inappropriate diuresis. The resulting hypernatremia and hyperosmolality required aggressive hypotonic fluid replacement to return to preoperative values. Though refractory to 1-desamino-8-D-argenine-vasopressin (dDAVP), thiazide diuretics and nonsteroidal anti-inflammatory agents have a role in managing selected patients. Early diagnosis with careful fluid and electrolyte management are critical in successful management of these patients in the perioperative period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978676

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

1.  Prolonged hypernatremia triggered by hyperglycemic hyperosmolar state with coma: A case report.

Authors:  Darlene Vigil; Kavitha Ganta; Yijuan Sun; Richard I Dorin; Antonios H Tzamaloukas; Karen S Servilla
Journal:  World J Nephrol       Date:  2015-05-06

2.  Massive postoperative polyuria following total gastrectomy for gastric cancer.

Authors:  Hiroharu Yamashita; Masahiro Ishimaru; Hironori Yamaguchi; Haruo Yamauchi; Arishige Sugiura; Joji Kitayama; Hirokazu Nagawa
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

3.  Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report.

Authors:  Shinobu Takayasu; Aya Kamba; Kazutaka Yoshida; Ken Terui; Yutaka Watanuki; Noriko Ishigame; Satoru Mizushiri; Tetsu Tomita; Kazuhiko Nakamura; Norio Yasui-Furukori; Makoto Daimon
Journal:  BMC Nephrol       Date:  2020-05-01       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.